Clinical trial
MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer
NCT00174369 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00174369 |
|---|---|
| Title | MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer |
| Official title | Phase 2 Study Of The MEK Inhibitor PD-0325901 In Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | PD-0325901 |
| Enrollment | 34 |
| Start date | Nov 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Mar 17, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: